GLP-1 Medications and Birth Control Pills: What the Absorption Research Actually Shows

Why This Question Keeps Coming Up

"I just started a weight-loss injection. Is my birth control pill still working?" It's a reasonable thing to ask. GLP-1 medications slow down how quickly the stomach empties, and an oral contraceptive has to pass through that same stomach before it can be absorbed.

The honest answer depends on which medication you take. For one drug in this class—tirzepatide—the official prescribing information contains a specific contraception warning. For semaglutide and liraglutide, the pharmacokinetic studies that exist did not find a clinically relevant effect on the pill. Below is what those studies and labels actually say.

How GLP-1 Drugs Affect the Stomach

GLP-1 receptor agonists delay gastric emptying, which is part of how they increase fullness. How large is the delay? A 2024 systematic review and meta-analysis in the American Journal of Gastroenterology pooled studies that measured gastric emptying with scintigraphy. The average half-emptying time was about 138 minutes on a GLP-1 drug versus about 95 minutes on placebo—a pooled difference of roughly 36 minutes. Studies using the acetaminophen absorption test did not find a significant delay.

The effect is also not constant. For tirzepatide, the label notes that the gastric-emptying delay is largest after the first dose and diminishes over time. That timing pattern is the key to the contraception advice below.

Tirzepatide: The One With a Label Warning

Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for weight management) is the GLP-1 medication with the clearest interaction data. In the study described in its FDA prescribing information, women took a combined oral contraceptive (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) together with a single 5 mg dose of tirzepatide. Compared with the pill alone:

• Peak levels (Cmax) of ethinyl estradiol, norgestimate and norelgestromin fell by 59%, 66% and 55%.
• Total exposure (AUC) fell by 20%, 21% and 23%.
• The time to peak was delayed by 2.5 to 4.5 hours.

Based on this, the Mounjaro label states that tirzepatide "may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying," and advises: "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation." The Zepbound label carries the same instruction. Both labels add that hormonal contraceptives that are not taken by mouth should not be affected.

A 2024 literature review in the Journal of the American Pharmacists Association reached a consistent conclusion: of six clinical studies, only the tirzepatide study showed a significant reduction in contraceptive hormone exposure, which the authors linked to tirzepatide's greater gastric-emptying effect and its dose-escalation schedule.

Semaglutide and Liraglutide: What the Studies Found

The data for other GLP-1 drugs look different.

• Semaglutide injection: In a study of 43 postmenopausal women with type 2 diabetes, steady-state semaglutide 1.0 mg did not reduce exposure to ethinyl estradiol/levonorgestrel. Ethinyl estradiol AUC was 11% higher and levonorgestrel AUC 20% higher, and peak levels stayed within bioequivalence limits (Kapitza et al., 2015).
• Oral semaglutide: In 25 healthy postmenopausal women, oral semaglutide did not affect ethinyl estradiol or levonorgestrel exposure or peak levels (Jordy et al., 2021).
• Liraglutide: Peak levels were 12–13% lower and reached about 1.5 hours later, but total exposure was not reduced—the authors found no clinically relevant reduction in bioavailability (Jacobsen et al., 2011).

Accordingly, the Wegovy (semaglutide) label lists ethinyl estradiol and levonorgestrel among drugs with no clinically significant pharmacokinetic differences, and it does not contain a backup-contraception instruction like tirzepatide's. One caveat: these studies were done in postmenopausal women and mostly at steady state, not during the first weeks of treatment.

Progestin-Only Pills

There are no published pharmacokinetic studies of progestin-only pills ("mini-pills") taken with a GLP-1 medication. Traditional norethindrone mini-pills have a narrow window—they need to be taken within about 3 hours of the same time each day—so anything that disturbs absorption leaves less margin. The tirzepatide label advice applies to all oral hormonal contraceptives, not only combined pills. If you use a mini-pill and are starting a GLP-1 drug, it's worth asking your prescriber or pharmacist which option fits you.

Vomiting and Diarrhea

Separately from gastric emptying, GLP-1 medications frequently cause gastrointestinal side effects, especially during dose increases. In the Wegovy label, nausea was reported by 44% of adults on semaglutide 2.4 mg versus 16% on placebo. Vomiting or severe diarrhea soon after taking a pill can reduce how much hormone you absorb, regardless of which GLP-1 drug you use.

If this happens, follow the vomiting and missed-pill instructions in your pill's package leaflet, and ask a pharmacist if you're unsure whether you need a backup method.

Oral Semaglutide and Pill Timing

Oral semaglutide (Rybelsus) has its own rules: take it on an empty stomach in the morning with no more than 4 ounces (about 120 mL) of water, and wait at least 30 minutes before eating, drinking or taking other oral medications. That means a contraceptive pill shouldn't be taken in that same 30-minute window. Beyond that, there's no evidence that spacing your pill a particular number of hours away from a GLP-1 dose improves contraceptive protection. Taking your pill consistently at the same time each day remains the most important habit.

Non-Oral Methods Avoid the Question

Methods that don't depend on stomach absorption—hormonal or copper IUDs, the implant, the injection, the patch and the vaginal ring—are not expected to be affected by gastric emptying. The tirzepatide labels state that non-oral hormonal contraceptives should not be affected. If reliable contraception is a high priority and you're starting tirzepatide, discussing a non-oral method with your clinician is one of the options the label itself points to.

If You're Planning a Pregnancy

Contraception and pregnancy planning go together here. The Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy because of its long half-life. If you take any GLP-1 medication and are pregnant or planning to become pregnant, tell your prescriber.

The Bottom Line

What the evidence supports:

• Tirzepatide: follow the label—switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
• Semaglutide and liraglutide: formal studies found no clinically relevant reduction in pill absorption, and their labels contain no comparable backup instruction.
• Any GLP-1 drug: vomiting or severe diarrhea can still compromise a pill, so follow your pill's instructions when it happens.

What we don't know: no large study has directly measured contraceptive failure rates in people taking oral contraceptives with GLP-1 medications. Tell both your GLP-1 prescriber and your pharmacist which contraceptive you use, so they can advise you on your specific combination.